Literature DB >> 25924066

Cancer: Antibodies regulate antitumour immunity.

Laurence Zitvogel1, Guido Kroemer2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25924066     DOI: 10.1038/nature14388

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  10 in total

1.  Immunogenic death of colon cancer cells treated with oxaliplatin.

Authors:  A Tesniere; F Schlemmer; V Boige; O Kepp; I Martins; F Ghiringhelli; L Aymeric; M Michaud; L Apetoh; L Barault; J Mendiboure; J-P Pignon; V Jooste; P van Endert; M Ducreux; L Zitvogel; F Piard; G Kroemer
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

2.  Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines.

Authors:  D Hannani; C Locher; T Yamazaki; V Colin-Minard; M Vetizou; L Aymeric; S Viaud; D Sanchez; M J Smyth; P Bruhns; G Kroemer; L Zitvogel
Journal:  Cell Death Differ       Date:  2013-06-07       Impact factor: 15.828

Review 3.  Natural innate and adaptive immunity to cancer.

Authors:  Matthew D Vesely; Michael H Kershaw; Robert D Schreiber; Mark J Smyth
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

Review 4.  Immunogenic cell death in cancer therapy.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Oliver Kepp; Laurence Zitvogel
Journal:  Annu Rev Immunol       Date:  2012-11-12       Impact factor: 28.527

5.  GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.

Authors:  Christian A Gerdes; Valeria Gonzalez Nicolini; Sylvia Herter; Erwin van Puijenbroek; Sabine Lang; Michaela Roemmele; Ekkehard Moessner; Olivier Freytag; Thomas Friess; Carola H Ries; Birgit Bossenmaier; Hans Joachim Mueller; Pablo Umaña
Journal:  Clin Cancer Res       Date:  2012-12-03       Impact factor: 12.531

Review 6.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Mark J Smyth; Guido Kroemer
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

Review 7.  Oncology meets immunology: the cancer-immunity cycle.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

8.  Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.

Authors:  Shabnam Shalapour; Joan Font-Burgada; Giuseppe Di Caro; Zhenyu Zhong; Elsa Sanchez-Lopez; Debanjan Dhar; Gerald Willimsky; Massimo Ammirante; Amy Strasner; Donna E Hansel; Christina Jamieson; Christopher J Kane; Tobias Klatte; Peter Birner; Lukas Kenner; Michael Karin
Journal:  Nature       Date:  2015-04-29       Impact factor: 49.962

Review 9.  Classification of current anticancer immunotherapies.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; José-Manuel Bravo-San Pedro; Aitziber Buqué; Laura Senovilla; Elisa Elena Baracco; Norma Bloy; Francesca Castoldi; Jean-Pierre Abastado; Patrizia Agostinis; Ron N Apte; Fernando Aranda; Maha Ayyoub; Philipp Beckhove; Jean-Yves Blay; Laura Bracci; Anne Caignard; Chiara Castelli; Federica Cavallo; Estaban Celis; Vincenzo Cerundolo; Aled Clayton; Mario P Colombo; Lisa Coussens; Madhav V Dhodapkar; Alexander M Eggermont; Douglas T Fearon; Wolf H Fridman; Jitka Fučíková; Dmitry I Gabrilovich; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Giuseppe Giaccone; Eli Gilboa; Sacha Gnjatic; Axel Hoos; Anne Hosmalin; Dirk Jäger; Pawel Kalinski; Klas Kärre; Oliver Kepp; Rolf Kiessling; John M Kirkwood; Eva Klein; Alexander Knuth; Claire E Lewis; Roland Liblau; Michael T Lotze; Enrico Lugli; Jean-Pierre Mach; Fabrizio Mattei; Domenico Mavilio; Ignacio Melero; Cornelis J Melief; Elizabeth A Mittendorf; Lorenzo Moretta; Adekunke Odunsi; Hideho Okada; Anna Karolina Palucka; Marcus E Peter; Kenneth J Pienta; Angel Porgador; George C Prendergast; Gabriel A Rabinovich; Nicholas P Restifo; Naiyer Rizvi; Catherine Sautès-Fridman; Hans Schreiber; Barbara Seliger; Hiroshi Shiku; Bruno Silva-Santos; Mark J Smyth; Daniel E Speiser; Radek Spisek; Pramod K Srivastava; James E Talmadge; Eric Tartour; Sjoerd H Van Der Burg; Benoît J Van Den Eynde; Richard Vile; Hermann Wagner; Jeffrey S Weber; Theresa L Whiteside; Jedd D Wolchok; Laurence Zitvogel; Weiping Zou; Guido Kroemer
Journal:  Oncotarget       Date:  2014-12-30

10.  Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity.

Authors:  Yaron Carmi; Matthew H Spitzer; Ian L Linde; Bryan M Burt; Tyler R Prestwood; Nicola Perlman; Matthew G Davidson; Justin A Kenkel; Ehud Segal; Ganesh V Pusapati; Nupur Bhattacharya; Edgar G Engleman
Journal:  Nature       Date:  2015-04-29       Impact factor: 49.962

  10 in total
  10 in total

Review 1.  Annexin A1: shifting the balance towards resolution and repair.

Authors:  Giovanna Leoni; Asma Nusrat
Journal:  Biol Chem       Date:  2016-10-01       Impact factor: 3.915

2.  Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion.

Authors:  Yi Wang; Xiaojuan Li; Yan-Hui Liu; Daisy Richardson; Huijuan Li; Mohammed Shameem; Xiaoyu Yang
Journal:  MAbs       Date:  2016-09-06       Impact factor: 5.857

3.  Deceleration of glycometabolism impedes IgG-producing B-cell-mediated tumor elimination by targeting SATB1.

Authors:  Jiajing Liu; Yifan Li; Zhou Lu; Jie Gu; Yun Liang; Enyu Huang; Zhiming Wang; Hushan Zhang; Luman Wang; Dan Zhang; Hongxiu Yu; Ronghua Liu; Yiwei Chu
Journal:  Immunology       Date:  2018-10-10       Impact factor: 7.397

4.  Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.

Authors:  Yong Wang; Cara C Schafer; Kenneth P Hough; Sultan Tousif; Steven R Duncan; John F Kearney; Selvarangan Ponnazhagan; Hui-Chen Hsu; Jessy S Deshane
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

Review 5.  The Bone Microenvironment: a Fertile Soil for Tumor Growth.

Authors:  Denise Buenrostro; Patrick L Mulcrone; Philip Owens; Julie A Sterling
Journal:  Curr Osteoporos Rep       Date:  2016-08       Impact factor: 5.096

Review 6.  CEACAM1 as a multi-purpose target for cancer immunotherapy.

Authors:  Matthew Dankner; Scott D Gray-Owen; Yu-Hwa Huang; Richard S Blumberg; Nicole Beauchemin
Journal:  Oncoimmunology       Date:  2017-05-16       Impact factor: 8.110

7.  Somatic mutation-associated T follicular helper cell elevation in lung adenocarcinoma.

Authors:  Kevin W Ng; Erin A Marshall; Katey Ss Enfield; Spencer D Martin; Katy Milne; Michelle E Pewarchuk; Ninan Abraham; Wan L Lam
Journal:  Oncoimmunology       Date:  2018-09-06       Impact factor: 8.110

8.  Pancreatic adenocarcinomas with mature blood vessels have better overall survival.

Authors:  Eriko Katsuta; Qianya Qi; Xuan Peng; Steven N Hochwald; Li Yan; Kazuaki Takabe
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

9.  HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.

Authors:  Marica Garziera; Ettore Bidoli; Erika Cecchin; Enrico Mini; Stefania Nobili; Sara Lonardi; Angela Buonadonna; Domenico Errante; Nicoletta Pella; Mario D'Andrea; Francesco De Marchi; Antonino De Paoli; Chiara Zanusso; Elena De Mattia; Renato Tassi; Giuseppe Toffoli
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

10.  Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma.

Authors:  Yang Li; Cheng-Qiang Li; Shu-Juan Guo; Wei Guo; He-Wei Jiang; He-Cheng Li; Sheng-Ce Tao
Journal:  EBioMedicine       Date:  2020-02-26       Impact factor: 8.143

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.